JP2025512865A5 - - Google Patents
Info
- Publication number
- JP2025512865A5 JP2025512865A5 JP2024557727A JP2024557727A JP2025512865A5 JP 2025512865 A5 JP2025512865 A5 JP 2025512865A5 JP 2024557727 A JP2024557727 A JP 2024557727A JP 2024557727 A JP2024557727 A JP 2024557727A JP 2025512865 A5 JP2025512865 A5 JP 2025512865A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- acid residues
- group
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210337315.XA CN116925215A (zh) | 2022-03-31 | 2022-03-31 | 抗血清白蛋白纳米抗体及其衍生物 |
| CN202210337315.X | 2022-03-31 | ||
| PCT/CN2023/085559 WO2023186120A1 (zh) | 2022-03-31 | 2023-03-31 | 抗血清白蛋白纳米抗体及其衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512865A JP2025512865A (ja) | 2025-04-22 |
| JP2025512865A5 true JP2025512865A5 (https=) | 2025-07-14 |
Family
ID=88199498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557727A Pending JP2025512865A (ja) | 2022-03-31 | 2023-03-31 | 抗血清アルブミンナノボディおよびその誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250223340A1 (https=) |
| EP (1) | EP4501957A1 (https=) |
| JP (1) | JP2025512865A (https=) |
| CN (2) | CN116925215A (https=) |
| AU (1) | AU2023245368A1 (https=) |
| CA (1) | CA3255200A1 (https=) |
| IL (1) | IL316006A (https=) |
| WO (1) | WO2023186120A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025147862A1 (zh) * | 2024-01-09 | 2025-07-17 | 上海洛启生物医药技术有限公司 | 血清白蛋白结合分子及其应用 |
| CN120025433A (zh) * | 2024-01-22 | 2025-05-23 | 寻济生物科技（北京）有限公司 | 一种抗白蛋白抗体或其抗原结合片段及其应用 |
| WO2025217579A1 (en) * | 2024-04-12 | 2025-10-16 | Paragon Therapeutics, Inc. | Anti-hsa vhh antibodies and compositions thereof |
| US12459994B2 (en) | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| WO2025228322A1 (zh) * | 2024-04-30 | 2025-11-06 | 上海赛增医疗科技有限公司 | 靶向血清白蛋白的单域抗体及融合蛋白 |
| CN118496355B (zh) * | 2024-07-12 | 2024-10-01 | 通化安睿特生物制药股份有限公司 | 抗血清白蛋白的纳米抗体及其衍生物和应用 |
| CN119708221B (zh) * | 2025-02-28 | 2025-06-17 | 长春生物制品研究所有限责任公司 | 靶向人血清白蛋白纳米抗体及应用 |
| CN120865399B (zh) * | 2025-09-22 | 2026-01-13 | 通化安睿特生物制药股份有限公司 | 白蛋白结合纳米抗体4c11及其衍生物和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8188223B2 (en) * | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| WO2014111550A1 (en) * | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| CN107674122A (zh) * | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | 一种识别人血清白蛋白的单域抗体 |
| CN111138537B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 一种抗人血清白蛋白抗体片段、制备方法和应用 |
| CN112409480B (zh) * | 2019-08-20 | 2024-08-27 | 四川科伦博泰生物医药股份有限公司 | 结合血清白蛋白的蛋白及其用途 |
| CN111057148B (zh) * | 2019-12-06 | 2021-06-18 | 南京融捷康生物科技有限公司 | 针对牛血清白蛋白bsa的单域抗体及其衍生蛋白 |
-
2022
- 2022-03-31 CN CN202210337315.XA patent/CN116925215A/zh active Pending
-
2023
- 2023-03-31 CN CN202380031741.3A patent/CN119032104A/zh active Pending
- 2023-03-31 JP JP2024557727A patent/JP2025512865A/ja active Pending
- 2023-03-31 IL IL316006A patent/IL316006A/en unknown
- 2023-03-31 CA CA3255200A patent/CA3255200A1/en active Pending
- 2023-03-31 AU AU2023245368A patent/AU2023245368A1/en active Pending
- 2023-03-31 EP EP23778484.8A patent/EP4501957A1/en active Pending
- 2023-03-31 US US18/852,902 patent/US20250223340A1/en active Pending
- 2023-03-31 WO PCT/CN2023/085559 patent/WO2023186120A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025512865A5 (https=) | ||
| TWI374891B (en) | Trimeric soluble antibody and the generating and using method thereof | |
| CN103619878B (zh) | 结合血清白蛋白的蛋白 | |
| JP2018087211A (ja) | 交差結合領域の配向性を有する二重可変領域抗体様結合タンパク質 | |
| AU2016208161B2 (en) | IL-17A-binding polypeptides | |
| CN113195530B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| CN101646689A (zh) | 具有长半衰期的血清清蛋白结合蛋白 | |
| RS55609B1 (sr) | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane | |
| CN103890246A (zh) | 可溶性多肽 | |
| CN108712908A (zh) | 自交联抗体 | |
| CN120484127A (zh) | 受约束的条件性活化的结合蛋白 | |
| IL316006A (en) | Anti-serum albumin nanobody and derivative thereof | |
| EP4303231A1 (en) | Bispecific antibody | |
| JP2024504777A (ja) | Ｍｕｌｔａｂｏｄｙ構築物、組成物および方法 | |
| JP2023531494A5 (https=) | ||
| JP7847284B1 (ja) | 上皮増殖因子受容体を標的とする組成物並びにその製造方法及び使用方法 | |
| TW202325744A (zh) | 用於ｈｉｖ之抗原結合多肽、抗原結合多肽複合物及其使用方法 | |
| WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
| TW202542179A (zh) | 經由異肽鍵形成之新穎多肽的製作方法 | |
| WO2026086930A1 (zh) | Tl1a结合分子及其应用 | |
| TW202430547A (zh) | 結合至nkg2a及pd-l1之藥劑及其用途 | |
| TW202436338A (zh) | Nkg2a結合劑及其用途 | |
| HK40121000A (en) | Anti-serum albumin nanobody and derivative thereof | |
| CN117843782A (zh) | 靶向人lilrb4的纳米抗体及其应用 | |
| HK40095576A (zh) | 双特异性抗体及其应用 |